Want to see CLRB full AI Analyst Report?
Total Valuation
Cellectar Biosciences has a market cap or net worth of $24.48M. The enterprise value is $1.54.
Market Cap$24.48M
Enterprise Value$1.54
Share Statistics
Cellectar Biosciences has 9,452,108 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding9,452,108
Owned by Insiders0.97%
Owned by Institutions23.18%
Financial Efficiency
Cellectar Biosciences’s return on equity (ROE) is -2.20 and return on invested capital (ROIC) is -222.48%.
Return on Equity (ROE)-2.20
Return on Assets (ROA)-1.45
Return on Invested Capital (ROIC)-222.48%
Return on Capital Employed (ROCE)-2.25
Revenue Per Employee0.00
Profits Per Employee-1.98M
Employee Count11
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cellectar Biosciences is ―. Cellectar Biosciences’s PEG ratio is 0.00458.
PE Ratio―
PS Ratio0.00
PB Ratio0.78
Price to Fair Value0.78
Price to FCF-0.33
Price to Operating Cash Flow-1.65
PEG Ratio0.00458
Income Statement
In the last 12 months, Cellectar Biosciences had revenue of 0.00 and earned -21.79M in profits. Earnings per share was -8.35.
Revenue0.00
Gross Profit-213.60K
Operating Income-22.98M
Pretax Income-21.79M
Net Income-21.79M
EBITDA-21.58M
Earnings Per Share (EPS)-8.35
Cash Flow
In the last 12 months, operating cash flow was -19.47M and capital expenditures -9.26K, giving a free cash flow of -19.48M billion.
Operating Cash Flow-19.47M
Free Cash Flow-19.48M
Free Cash Flow per Share-2.06
Dividends & Yields
Cellectar Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.28
52-Week Price Change-40.59%
50-Day Moving Average2.56
200-Day Moving Average2.98
Relative Strength Index (RSI)52.88
Average Volume (3m)110.32K
Important Dates
Cellectar Biosciences upcoming earnings date is Oct 29, 2026, TBA (Confirmed).
Last Earnings DateAug 13, 2026
Next Earnings DateOct 29, 2026
Ex-Dividend Date―
Financial Position
Cellectar Biosciences as a current ratio of 2.96, with Debt / Equity ratio of 5.13%
Current Ratio2.96
Quick Ratio2.96
Debt to Market Cap0.00
Net Debt to EBITDA0.59
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cellectar Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Cellectar Biosciences EV to EBITDA ratio is 0.24, with an EV/FCF ratio of 0.22.
EV to Sales0.00
EV to EBITDA0.24
EV to Free Cash Flow0.22
EV to Operating Cash Flow0.22
Balance Sheet
Cellectar Biosciences has $33.99M in cash and marketable securities with $1.53M in debt, giving a net cash position of $32.46M billion.
Cash & Marketable Securities$33.99M
Total Debt$1.53M
Net Cash$32.46M
Net Cash Per Share$3.43
Tangible Book Value Per Share$3.80
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Cellectar Biosciences is $11.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$11.67
Price Target Upside384.09% Upside
Analyst ConsensusStrong Buy
Analyst Count3
Revenue Growth Forecast―
EPS Growth Forecast77.68%